Literature DB >> 24976072

Issues with implementing a high-quality lung cancer screening program.

James L Mulshine1, Thomas A D'Amico.   

Abstract

After a comprehensive review of the evidence, the United States Preventive Services Task Force recently endorsed screening with low-dose computed tomography as an early detection approach that has the potential to significantly reduce deaths due to lung cancer. Prudent implementation of lung cancer screening as a high-quality preventive health service is a complex challenge. The clinical evaluation and management of high-risk cohorts in the absence of symptoms mandates an approach that differs significantly from that of symptom-detected lung cancer. As with other cancer screenings, it is essential to provide to informed at-risk individuals a safe, high-quality, cost-effective, and accessible service. In this review, the components of a successful screening program are discussed as we begin to disseminate lung cancer screening as a national resource to improve outcomes with this lethal cancer. This information about lung cancer screening will assist clinicians with communications about the potential benefits and harms of this service for high-risk individuals considering participation in the screening process.
© 2014 American Cancer Society.

Entities:  

Keywords:  American Academy of Family Physicians (AAFP); American Association of Physicists in Medicine (AAPM); Centers for Medicaid and Medicare Services (CMS); National Lung Screening Trial (NLST); Nederlands-Leuvens Longkanker Screenings ONderzoek (NELSON) trial; Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial; US Preventive Services Task Force (USPSTF).; chest x-ray (CXR); low-dose computed tomography (LDCT); lung cancer screening

Mesh:

Year:  2014        PMID: 24976072     DOI: 10.3322/caac.21239

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  30 in total

1.  Controlled settings for lung cancer screening: why do they matter? Considerations for referring clinicians.

Authors:  A Bharmal; A Crosskill; S Lam; H Bryant
Journal:  Curr Oncol       Date:  2016-12-21       Impact factor: 3.677

2.  Recommendations from the European Society of Thoracic Surgeons (ESTS) regarding computed tomography screening for lung cancer in Europe.

Authors:  Jesper Holst Pedersen; Witold Rzyman; Giulia Veronesi; Thomas A D'Amico; Paul Van Schil; Laureano Molins; Gilbert Massard; Gaetano Rocco
Journal:  Eur J Cardiothorac Surg       Date:  2017-03-01       Impact factor: 4.191

3.  Implementing computed tomography-based lung cancer screening in the community.

Authors:  James L Mulshine; Laurie Fenton Ambrose
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

Review 4.  Implementation and organization of lung cancer screening.

Authors:  Jesper Holst Pedersen; Haseem Ashraf
Journal:  Ann Transl Med       Date:  2016-04

5.  Status of lung cancer screening.

Authors:  James L Mulshine
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

6.  Patient navigation for lung cancer screening in an urban safety-net system: Protocol for a pragmatic randomized clinical trial.

Authors:  David E Gerber; Heidi A Hamann; Noel O Santini; Suhny Abbara; Hsienchang Chiu; Molly McGuire; Lisa Quirk; Hong Zhu; Simon J Craddock Lee
Journal:  Contemp Clin Trials       Date:  2017-07-05       Impact factor: 2.226

Review 7.  Risk factors assessment and risk prediction models in lung cancer screening candidates.

Authors:  Mariusz Adamek; Ewa Wachuła; Sylwia Szabłowska-Siwik; Agnieszka Boratyn-Nowicka; Damian Czyżewski
Journal:  Ann Transl Med       Date:  2016-04

8.  Evaluation of Promotional Materials To Promote Low-Dose Computed Tomography (LDCT) Screening to High-Risk Consumers and Health Care Providers.

Authors:  Janella N Hudson; Gwendolyn P Quinn; Lauren E Wilson; Vani N Simmons
Journal:  J Cancer Educ       Date:  2018-10       Impact factor: 2.037

9.  Association between different sequences of vessel ligation during video-assisted thoracoscopic lobectomy and survival in patients with non-small cell lung cancer.

Authors:  Huang-He He; Jia-Xi He; Zhe-Xue Hao; Wei Wang; Jian-Xing He
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

10.  Automatic Lung-RADS™ classification with a natural language processing system.

Authors:  Sebastian E Beyer; Brady J McKee; Shawn M Regis; Andrea B McKee; Sebastian Flacke; Gilan El Saadawi; Christoph Wald
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.